Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXA-A1.1 Tablet Size and Fasting Status PD Study
NCT03121339Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VXA-A1.1 in influenza A H1N1 infection (H1N1) (2 arms), sponsored by Vaxart, Inc. Primary endpoints: Location of disintegration at 7 days and Time to disintegration at 7 days. Started Mar 2017; status: completed.
02
Drugs
VXA-A1.1
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT03121339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121339.